TMDX— AI Stock Forecast & Price Targets
Published 7/29/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX is a category-leading organ preservation platform with elite underlying unit economics (45% ROE, 59% GM, 30% TTM sales growth) but faces a binary Aug 4 earnings print in ~6 days where a four-quarter operating margin collapse (23.2%→7.6%) and FCF flip to -$12M must reverse. Price at $76.29 has broken modestly above the $65-$75 range but sits 51% below the 52W high with 23% short float and options pricing a ~15% move — this is a HOLD into the print, with any pre-earnings sizing treated as speculation, not investment.
HOLD into Aug 4 earnings (~6 days away). Do NOT initiate a full swing position — the print is binary with options implying >15% move and 23% short float amplifying both directions. If forced to act, a small (¼ size) pre-earnings starter around $74-76 is defensible only for accounts with high risk tolerance; sized appropriately, defined-risk options (long call spread or short put spread below $65) are the cleaner expression. Key levels: $80 is the first technical resistance (weekly close above = trend repair), $75 is pivot, $70 support, $65 is bear-case backstop, $60 is invalidation of the recovery entirely. Earnings itself is the invalidation event — a print that fails to show operating margin recovery above ~12% and FCF returning positive would break the thesis.
1-6 month view hinges entirely on whether Q2 shows sequential margin recovery. Base case: Q2 op margin recovers to 12-15% (still below Q2'25's 23%), FCF turns positive, guidance is reaffirmed, and the stock re-rates into the $85-92 zone as short covering combines with sell-side upgrades. Bull case: margin snaps back toward 18%+ confirming the temporary-capex narrative, kidney/European commentary is concrete, and the stock reclaims $100+. Bear case: margin stays sub-10% and/or FCF stays negative, guidance is trimmed, and the stock retests $60-65. Expected return range: -20% to +25% skewed slightly positive given the setup (short interest, oversold longer-term, analyst support). What would change my mind: a clean beat on margin AND FCF would warrant upgrading to ACCUMULATE at any level below $90.
1-3 year terminal thesis: TMDX is building the logistics backbone of organ transplantation with a genuine moat (only FDA-approved OCS platform, 22-aircraft NOP network, 1,000+ transplant center relationships). If OCS Kidney launches on time (late 2026/early 2027), European rollout via PAD Aviation executes by 2027, and operating leverage from the NOP capex investment materializes, the business can plausibly sustain 20%+ revenue growth with mid-teens operating margins, supporting a valuation well north of $120. Biggest structural risk: the vertical integration into aviation/logistics may have permanently reset the margin profile lower than the pure-device era, meaning the market never awards the old 40x+ multiple again. Secondary risks: reimbursement policy shifts, competitive perfusion technology, and clinical trial setbacks in the DENOVO Lung / ENHANCE Heart programs.
The fundamental picture is bifurcated between a strong long-term franchise and a deteriorating near-term trajectory. On the positive side: TTM revenue of $635.9M with 30.2% Y/Y growth, gross margin steady at 58-61%, ROE of 45.2%, ROIC of 12.8%, and a $461.7M cash cushion give the business a clear quality floor. Q1 2026 revenue of $173.9M was up 21% YoY and management reaffirmed $727-757M FY26 guidance. However, the trajectory of profitability is the central problem: operating margin has collapsed sequentially from 23.2% (Q2'25) → 16.2% (Q3'25) → 13.2% (Q4'25) → 7.6% (Q1'26), and free cash flow flipped from +$82.5M in Q2'25 to -$12.1M in Q1'26 as capex spiked to $36.7M for the NOP aviation buildout. Total debt jumped from $519M to $863M in a single quarter (funded by the $400M convertible), pushing debt/equity to 1.75. EPS Q/Q is -71.2%. The bull case requires believing this is temporary capex-driven margin compression tied to fleet ramp; the bear case is that logistics is structurally lower-margin than the pure device business. Aug 4 will resolve the dispute.
Across timeframes, the stock is attempting a repair off a deep drawdown but is not yet in a confirmed uptrend. The 1h chart shows a clean stair-step higher from ~$68 to $75.95 over July, with the forecast band projecting a violent gap to $99 — this is noise given the model's realized 1wk directional accuracy is 0% vs an 83% naive baseline, so the forecast should be heavily discounted. The 4h/1d charts show price recovering from the May capitulation low near $60, now testing the underside of the prior $75-80 supply zone. The weekly chart reveals the damage: down 51% from the $156 high, still 30% below the 200-day SMA, and only recently reclaiming the 20/50-day SMAs (+5.4%/+6.4% distances). RSI of 56.6 is constructive but not overbought. The critical technical level remains a weekly close above $80 — that has not printed and has repeatedly failed. Short interest at 23.2% of float (5.7 days-to-cover) creates squeeze potential on a positive print but is also a warning that sophisticated money is skeptical. Perf Half Y of -45% and YTD -37% frame this as a broken chart in repair mode, not a momentum name.
The signal in the recent news flow is that the sell-side has moderated but remains constructive: TD Cowen reiterated Buy with a $120 PT, Evercore lowered from $100 to $90 but kept Outperform, and Piper Sandler is at $120 highlighting the $2.2B US kidney opportunity. Consensus target sits at $112.89 with a Recom score of 1.64 (strong buy skew). A Seeking Alpha piece explicitly frames the thesis as 'The Margins Must Recover,' which mirrors our own bear/bull pivot point. Motley Fool and others frame the -45% drawdown as a growth-at-reasonable-price opportunity. The noise: the class-action litigation flagged in deep research and generic 'affordable growth stock' takes. The single most actionable news item is the confirmed Aug 4 AMC earnings date — everything else is context. Social sentiment is split 50/50, with retail explicitly noting that straddles are pricing a >15% move, confirming the binary event risk.
- OCS Kidney launch targeted late 2026/early 2027 addressing a $2.2B US TAM (Piper Sandler estimate), diversifying away from ~80% liver concentration
- European expansion via PAD Aviation GmbH acquisition (Jun 2026) targeting pan-European OCS rollout by 2027
- NOP national transplant network scaled to 22 aircraft and 1,000+ transplant centers — operating leverage should emerge as utilization ramps against the $344M capacity investment
- Next-Gen OCS DENOVO Lung and ENHANCE Heart trials (FDA IDE approvals Feb 2026) supporting Q2-Q4 2026 launch pipeline
- FY26 guidance reaffirmed at $727-757M (20-25% growth) providing near-term revenue floor
- Aug 4 earnings binary risk with options pricing >15% move and 23% short float amplifying both directions
- Structural operating margin compression (23.2%→7.6% over four quarters) may reflect permanent logistics-driven margin reset, not temporary capex
- Debt jumped from $519M to $863M in one quarter (D/E 1.75); combined with negative FCF, increases sensitivity to any utilization stall
- Revenue concentration in liver OCS (~80%) creates single-product reimbursement/competitive risk
- Class-action litigation alleging fraud around historical OCS FDA scrutiny remains an overhang
- Weekly close above $80 has repeatedly failed — technical resistance is real and consensus $112 targets have not printed
- Model's own 1wk directional accuracy is 0% vs 83% naive baseline — the bullish forecast spike should not be trusted
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord